Suppr超能文献

胰腺腺鳞癌手术后的临床病理特征及预后

Clinicopathologic features and outcomes following surgery for pancreatic adenosquamous carcinoma.

作者信息

Hsu Jun-Te, Chen Han-Ming, Wu Ren-Chin, Yeh Chun-Nan, Yeh Ta-Sen, Hwang Tsann-Long, Jan Yi-Yin, Chen Miin-Fu

机构信息

Department of Surgery, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.

出版信息

World J Surg Oncol. 2008 Sep 3;6:95. doi: 10.1186/1477-7819-6-95.

Abstract

BACKGROUND

Pancreatic adenosquamous carcinoma (ASC) is a rare pancreatic malignancy subtype. We investigated the clinicopathological features and outcome of pancreatic ASC patients after surgery.

METHODS

The medical records of 12 patients with pancreatic ASC undergoing surgical treatment (1993 to 2006) were retrospectively reviewed. Survival data of patients with stage IIB pancreatic adenocarcinoma and ASC undergoing surgical resection were compared.

RESULTS

Symptoms included abdominal pain (91.7%), body weight loss (83.3%), anorexia (41.7%) and jaundice (25.0%). Tumors were located at pancreatic head in 5 (41.7%) patients, tail in 5 (41.7%), and body in 4 (33.3%). Median tumor size was 6.3 cm. Surgical resection was performed on 7 patients, bypass surgery on 3, and exploratory laparotomy with biopsy on 2. No surgical mortality was identified. Seven (58.3%) and 11 (91.7%) patients died within 6 and 12 months of operation, respectively. Median survival of 12 patients was 4.41 months. Seven patients receiving surgical resection had median survival of 6.51 months. Patients with stage IIB pancreatic ASC had shorter median survival compared to those with adenocarcinoma.

CONCLUSION

Aggressive surgical management does not appear effective in treating pancreatic ASC patients. Strategies involving non-surgical treatment such as chemotherapy, radiotherapy or target agents should be tested.

摘要

背景

胰腺腺鳞癌(ASC)是一种罕见的胰腺恶性肿瘤亚型。我们研究了胰腺ASC患者术后的临床病理特征及预后。

方法

回顾性分析1993年至2006年期间接受手术治疗的12例胰腺ASC患者的病历。比较IIB期胰腺腺癌和ASC接受手术切除患者的生存数据。

结果

症状包括腹痛(91.7%)、体重减轻(83.3%)、厌食(41.7%)和黄疸(25.0%)。肿瘤位于胰头5例(41.7%),胰尾5例(41.7%),胰体4例(33.3%)。肿瘤中位大小为6.3 cm。7例患者接受了手术切除,3例接受了旁路手术,2例接受了剖腹探查活检。未发现手术死亡病例。分别有7例(58.3%)和11例(91.7%)患者在术后6个月和12个月内死亡。12例患者的中位生存期为4.41个月。7例接受手术切除的患者中位生存期为6.51个月。与腺癌患者相比,IIB期胰腺ASC患者的中位生存期较短。

结论

积极的手术治疗似乎对胰腺ASC患者无效。应测试包括化疗、放疗或靶向药物等非手术治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0364/2543014/37cdd43079a0/1477-7819-6-95-1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验